Ocular hypotensive effects of an intratracheally delivered liposomal Δ9-tetrahydrocannabinol preparation in rats

Journal of Ocular Pharmacology and Therapeutics

Volumn 22, Issue 3, 2006, Pages 160-167

  Szczesniak, Anna Maria ^a   Kelly, Melanie E M ^a   Whynot, Sara ^a   Shek, Pang N ^b   Hung, Orlando ^a,c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABIS; DRONABINOL; LIPOSOME; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENZYME ACTIVATION; FIRST PASS EFFECT; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; MOLECULAR CLONING; NEUROPROTECTION; NONHUMAN; RAT; RETINA GANGLION CELL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; INTRAOCULAR PRESSURE; LIPOSOMES; RATS; RATS, INBRED BN; RECEPTOR, CANNABINOID, CB1; TETRAHYDROCANNABINOL;

EID: 33745889335     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2006.22.160     Document Type: Article

References (47)

1. Grotenhermen, F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet. 42:327-360, 2003.
2. Järvinen T., Pate, D.W., and Laine, K. Cannabinoids in the treatment of glaucoma. Pharmacol. Therap. 95:203-220, 2002.
3. Tomida, I., Pertwee, R.G., and Azura-Blanco, A. Cannabinoids and glaucoma. Br. J. Ophthalmol. 88:708-713, 2004.
4. Hepler, R.S., and Frank, I.M. Marihuana smoking and intraocular pressure. JAMA 217:1392, 1971.
5. Pate, D.W., Järvinen, K., Urtti, A., et al. Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sci. 48:1881-1893, 1998.
6. Song, Z., and Slowey, C. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55,212-2. JPET 292:136-139, 2000.
7. Bensaid, M., Gary-Bobo, M., Esclangon, A., et al. The cannabinoid CB1 receptor antagonist SR141716A increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats in cultured adipocyte cells. Mol. Pharmacol. 63:908-914, 2003.
8. Howlett, A.C., Breivogel, C.S., Childers, S.R., et al. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47(Sl1):345-358, 2004.
9. Rueda, D., Galve-Roperh, I., Haro, A., et al. The CB1 cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinases. Mol. Pharmacol. 58:814-820, 2000.
10. Porcella, A., Maxia, C., Gessa, G.L., et al. The human eye expresses high levels of CB1 cannabinoid receptor mRNA and protein. Eur. J. Neurosci. 12:1123-1127, 2000.
11. Stamer, W.D., Golightly, S.F., Hosohata, Y., et al. Cannabinoid CB1 receptor expression, activation, and detection of endogenous ligand in trabecular mesh-work and ciliary process tissues. Eur. J. Pharmacol. 431:277-286, 2001
12. Chien, F.Y., Wang, R.F., Mittag, T.W., et al. Effects of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Arch. Ophthalmol. 121:87-90, 2003.
13. Mittag, T., and Schmidt, K.G. Mechanisms of neuro protection against glaucoma. Ophthalmologe 101:1076-1086, 2004.
14. Porcella, A., Maxia, C., Gessa, G.L., et al. The synthetic cannabinoid WIN55,212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies. Eur. J. Neurosci. 13:409-412, 2001.
15. Quigley, H.A. Neuronal death in glaucoma. Prog. Retin. Eye Res. 18:39-57, 1999.
16. Coleman, A.L., Lerner, F., Bernstein, P., et al. A 3-month, randomized, controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension. Ophthalmology 110:2362-2368, 2003.
17. El-Remessy, A.B., Khalil, I.E., Matragoon, S., et al. Neuroprotective effect of (-) delta-9-tetrahydrocannabinol and cannabidiol in N-methyl-D-asparate-induced retinal neurotoxicity: Involvement of peroxynitre. Am. J. Pathol. 163:1997-2008, 2003.
18. Yoles, E., Belkin, M., and Schwartz, M. HU-211, a nonpsychoactive cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. J. Neurotraum. 13:49-57, 1996.
19. Hampson, A.J., Bornheim, L.M., Scanziani, M., et al. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J. Neurochem. 70:671-676, 1998.
20. Marsicano, G., Moosmann, B., Hermann, H., et al. Neuroprotective properties of cannabinoids against oxidative stress: Role of the cannabinoid receptor CB1. J. Neurochem. 80:448-456, 2002.
21. Matthias, P., Tashkin, D.P., Marques-Magallanes, J.A., et al. Effects of varying marijuana potency on deposition of tar and delta-9-THC in the lung during smoking. Pharmacol. Biochem. Behav. 58:1145-1150, 1997.
22. Pan, J., Tremblay, F., Archibald, M.L., et al. Noninvasive measurement of intraocular pressure in the conscious rat with Tonopen tonometer (ARVO Abstract). Inv. Opthalmol. Vis. Sci. 41:5897, Abstract nr 4771, 2000.
23. Meisner, D., Pringle, J., and Mezei, M. Liposomal pulmonary drug delivery: In vivo disposition of atropine base in solution and liposomal form following endotracheal installation to the rabbit lung. J. Microencapsul. 6:379-387, 1989.
24. Hung, O.R., Whynot, S., Varvel, J.R., et al. Pharmacokinetics of inhaled liposome-encapsulated fentanyl. Anaesthesiology 83:277-284, 1995.
25. Hung, O.R., Zamecnik, T.P., and Shek, P.N. Pulmonary delivery of liposome-encapsulated Δ9-tetrahydrocannabinol (Δ9-THC), in United States Patent Office. USA, 1999.
26. Beck, S.E., Jones, L. A., Chesnut, K., et al. Repeated delivery of adeno-associated virus vector to the rabbit airway. J. Virol. 73:9446-9455, 1999.
27. Rees, D.D., and Brain, J.D. Effects of cystic fibrosis airway secretions on rat lung: Role of neutrophil elastase. Am. J. Physiol. 269:L195-L202, 1995.
28. Rees, D.D., Rogers, R.A., Cooley, J., et al. Recombinant human monocyte/neutrophil elastase inhibitor protects rat lungs against injury from cystic fibrosis airway secretions. Am. J. Respir. Cell Mol. Biol. 20:69-78, 1999.
29. van Helden, H.P., Kuijpers, W.C., Steenvoorden, D., et al. Intratracheal aerosolization of endotoxin (LPS) in the rat: A comprehensive animal model to study adult (acute) respiratory distress syndrome. Exp. Lung Res. 23:297-316, 1997.
30. Fredrick, D.L., and Fowler, M.W. Comparison of six cannabinoid metabolite assays. J. Anal. Toxicol. 9:116-120, 1985.
31. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. 4:145-160, 2005.
32. Nagayasu, A., Uchiyama, K., and Kiwada, H. The size of liposomes: A factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv. Drug Deliv. Rev. 40:75-87, 1999.
33. Allen, T.M., Hansen, C.B., Martin, F., et al. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta. 1066:29, 2000.
34. Lichtman, A.H., Peart, J., Poklis, J.L., et al. Pharmacological evaluation of aerosolized cannabinoids in mice. Eur. J. Pharmacol. 399:141-149, 2000.
35. Straiker, A.J., Maguire, G., Mackie, K., et al. Localization of the cannabinoid receptors in human anterior eye and retina. Invest. Ophthalmol. Vis. Sci. 40:2442-2448, 1999.
36. Porcella, A., Casellas, P., Gessa, G.L., et al. Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: Implications for the antiglaucoma properties of marihuana. Mol. Brain Res. 58:240-245, 1998.
37. Sugrue, M.F., Funk, H.A., Leonard, Y., et al. The ocular hypotensive effects of synthetic cannabinoids. Invest. Opthalmol. Vis. Sci. 37:5831, 1996.
38. Rosen, G.H. Pharmacological used for nutritional disorders of HIV/AIDS. J. Physicians Assoc. AIDS Care 2:30-32, 1995.
39. Lemberger, L., Martz, R., Rodda, B., et al. Comparative pharmacology of delta-9-tetrahydrocannabinol and its metabolite; 11-OH-Delta9- tetrahydrocannabinol. J. Clin. Invest. 52:2411-2417, 1973.
40. Wall, M.E., and Perez-Reyes, M. The metabolism of delta-9- tetrahydrocannabinol and related cannabinoids in man. J Clin. Pharmacol. 21:178S-189S, 1981.
41. Brenneisen, R.,Egli, A., Elsohly, M.A., et al. The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: A pilot study with 2 patients. Int J. Clin. Pharmacol. Ther. 34:446-452, 1996.
42. Chiang, C.-W., Barnett, G., and Brine, D. Systemic absorption of Δ9-tetrahydrocannabinol after ophthalmic administration to the rabbit. J. Pharm. Sci. 72:136-138, 1983.
43. Green, K.A., and Kearse, C.E. Ocular penetration of delta-9- tetrahydrocannabinol from rabbit corneal or cul-de-sac application site. Curr. Eye Res. 21:566-570, 2000.
44. 2-receptor agonist, JWH-133, does not decrease intraocular pressure (IOP) in normotensive rabbits. Life Sci. 72:837-842, 2003.
45. Medical News Today. "New synthetic delta-9-THC Inhaler offers safe, rapid delivery, Phase 1study." April 17, 2005. Online document at: www.medicalnewstoday.com/medicalnews.php?newsid = 22937 Accessed April 17, 2006.
46. Myers, M.A., Thomas, D.A., Straub, L., et al. Pulmonary effects of chronic exposure to liposome aerosols in mice. Exp. Lung Res. 19:1-19, 1993.
47. Thomas, D.A., Myers, M.A., Wichert, B., et al. Acute effects of liposome aerosol inhalation on pulmonary function in healthy human volunteers. Chest 99:1268-1270, 1991.